question_id,date,category,question_text,baseline_success,baseline_actually_answered,baseline_has_expected,baseline_confidence,baseline_text,baseline_error,baseline_error_type,baseline_time,baseline_input_tokens,baseline_output_tokens,togomcp_success,togomcp_has_expected,togomcp_confidence,togomcp_text,togomcp_error,togomcp_error_type,togomcp_suggestion,togomcp_time,togomcp_input_tokens,togomcp_output_tokens,togomcp_cache_creation_input_tokens,togomcp_cache_read_input_tokens,tools_used,tool_details,value_add,expected_answer,notes
97,2026-02-01,Structured Query,Find marketed drugs that target both kinases and have mechanism of action data available.,True,True,True,0.8,"I can help you find marketed drugs that target kinases with mechanism of action data.

Based on my training knowledge, here are some prominent examples of marketed drugs that target kinases:

## Multi-Kinase Inhibitors:

1. **Sorafenib (Nexavar)** - targets VEGFR, PDGFR, RAF kinases; used for renal cell carcinoma and hepatocellular carcinoma

2. **Sunitinib (Sutent)** - targets VEGFR, PDGFR, KIT, FLT3; used for renal cell carcinoma and GIST

3. **Pazopanib (Votrient)** - targets VEGFR, PDGFR, KIT; used for renal cell carcinoma

4. **Dasatinib (Sprycel)** - targets BCR-ABL, SRC family kinases; used for CML and ALL

5. **Ponatinib (Iclusig)** - targets BCR-ABL (including T315I mutation), VEGFR, FGFR; used for CML and ALL

## Selective Kinase Inhibitors:

6. **Imatinib (Gleevec)** - targets BCR-ABL, KIT, PDGFR; used for CML and GIST

7. **Erlotinib (Tarceva)** - targets EGFR; used for NSCLC and pancreatic cancer

8. **Lapatinib (Tykerb)** - targets EGFR and HER2; used for breast cancer

9. **Ibrutinib (Imbruvica)** - targets BTK; used for various B-cell malignancies

10. **Ruxolitinib (Jakafi)** - targets JAK1/JAK2; used for myelofibrosis

These drugs all have well-documented mechanisms of action involving kinase inhibition and are approved for clinical use.",,,7.770580053329468,53,475,True,True,0.6,"Based on all the information I've gathered, I now have comprehensive data about marketed kinase inhibitor drugs. Let me compile and present this information to the user.

## Marketed Drugs Targeting Kinases with Mechanism of Action Data

I found numerous marketed drugs (phase 4 development) that target kinases and have mechanism of action data available in ChEMBL. Here are the key findings:

### Top Marketed Kinase Inhibitor Drugs (by number of kinase targets):

| Drug Name | Number of Kinase Targets | Drug Class |
|-----------|--------------------------|------------|
| **Imatinib** | 386 | Multi-kinase inhibitor |
| **Lapatinib** | 378 | Dual EGFR/HER2 inhibitor |
| **Erlotinib** | 377 | EGFR inhibitor |
| **Sunitinib** | 377 | Multi-kinase inhibitor |
| **Gefitinib** | 376 | EGFR inhibitor |
| **Quizartinib** | 375 | FLT3 inhibitor |
| **Crizotinib** | 371 | ALK/ROS1 inhibitor |
| **Tofacitinib** | 366 | JAK inhibitor |
| **Bosutinib** | 366 | BCR-ABL inhibitor |
| **Nilotinib** | 363 | BCR-ABL inhibitor |
| **Axitinib** | 361 | VEGFR inhibitor |
| **Afatinib** | 359 | Pan-ErbB inhibitor |
| **Ruxolitinib** | 359 | JAK1/JAK2 inhibitor |
| **Ibrutinib** | 213 | BTK inhibitor |
| **Ponatinib** | 201 | Multi-kinase inhibitor |
| **Cabozantinib** | 201 | VEGFR/MET inhibitor |
| **Trametinib** | 239 | MEK inhibitor |
| **Baricitinib** | 196 | JAK1/JAK2 inhibitor |

### Example: Imatinib Target Profile

Imatinib (CHEMBL941), one of the most well-studied kinase inhibitors, shows activity against multiple kinase targets including:

- **Tyrosine-protein kinase ABL** (primary target)
- Tyrosine-protein kinase FYN
- Receptor protein-tyrosine kinase erbB-2
- Tyrosine-protein kinase JAK3
- Tyrosine-protein kinase BLK
- cAMP-dependent protein kinase (PKA)
- Multiple MAP kinases and their upstream kinases
- Cyclin-dependent kinases
- Serine/threonine-protein kinases

### Key Categories of Marketed Kinase Inhibitors:

1. **BCR-ABL Inhibitors**: Imatinib, Dasatinib, Nilotinib, Bosutinib, Ponatinib
2. **EGFR/ErbB Inhibitors**: Erlotinib, Gefitinib, Afatinib, Lapatinib, Osimertinib
3. **JAK Inhibitors**: Ruxolitinib, Tofacitinib, Baricitinib, Upadacitinib, Fedratinib
4. **BTK Inhibitors**: Ibrutinib, Acalabrutinib, Zanubrutinib
5. **MEK Inhibitors**: Trametinib, Cobimetinib, Selumetinib, Binimetinib
6. **ALK Inhibitors**: Crizotinib, Ceritinib, Alectinib, Lorlatinib
7. **Multi-target VEGFR Inhibitors**: Sunitinib, Axitinib, Lenvatinib, Cabozantinib

All of these drugs have **comprehensive mechanism of action data available** in ChEMBL, including:
- Bioactivity data against multiple kinase targets
- Development phase information (all are phase 4/marketed)
- Clinical indication data
- Target selectivity profiles

The ChEMBL database contains extensive experimental data on these drugs' interactions with hundreds of kinases, making it an excellent resource for understanding their mechanism of action and off-target effects.",,,,138.76253700256348,62,6664,53189,559893,"mcp__togomcp__search_chembl_target, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql","[{""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""kinase"", ""limit"": 50}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?drug ?drugName ?target ?targetName ?mechanism\nWHERE {\n  ?drug a chembl:SmallMolecule ;\n        rdfs:label ?drugName ;\n        chembl:hasActivity ?activity ;\n        chembl:hasMechanism ?mechanism .\n  \n  ?activity chembl:hasAssay ?assay .\n  ?assay chembl:hasTarget ?target .\n  \n  ?target rdfs:label ?targetName ;\n          chembl:targetType ?targetType .\n  \n  ?mechanism chembl:hasMechanismOfAction ?moa ;\n             chembl:actionType ?actionType .\n  \n  # Filter for kinase targets\n  FILTER(CONTAINS(LCASE(?targetName), \""kinase\""))\n  \n  # Filter for marketed drugs\n  ?drug chembl:highestDevelopmentPhase \""4\""^^<http://www.w3.org/2001/XMLSchema#integer> .\n}\nLIMIT 100""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?molecule ?moleculeName ?maxPhase\nWHERE {\n  ?molecule a chembl:SmallMolecule ;\n            rdfs:label ?moleculeName ;\n            chembl:highestDevelopmentPhase ?maxPhase .\n  \n  # Filter for marketed drugs (phase 4)\n  FILTER(?maxPhase = \""4\""^^<http://www.w3.org/2001/XMLSchema#integer>)\n  \n  # Filter for kinase inhibitors by name\n  FILTER(CONTAINS(LCASE(?moleculeName), \""kinase\"") || \n         CONTAINS(LCASE(?moleculeName), \""tinib\"") ||\n         CONTAINS(LCASE(?moleculeName), \""imatinib\"") ||\n         CONTAINS(LCASE(?moleculeName), \""dasatinib\""))\n}\nLIMIT 50""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?moleculeName ?targetName ?actionType ?moaDescription\nWHERE {\n  VALUES ?molecule {\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL941>\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL1421>\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL1873475>\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL1789941>\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL2105759>\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL1173655>\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL2103875>\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL2403108>\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL288441>\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL3286830>\n  }\n  \n  ?molecule rdfs:label ?moleculeName ;\n            chembl:hasMechanism ?mechanism .\n  \n  ?mechanism chembl:hasMechanismOfAction ?moa .\n  \n  ?moa chembl:hasTarget ?target ;\n       chembl:actionType ?actionType .\n  \n  OPTIONAL { ?moa rdfs:comment ?moaDescription }\n  \n  ?target rdfs:label ?targetName .\n  \n  FILTER(CONTAINS(LCASE(?targetName), \""kinase\""))\n}\nORDER BY ?moleculeName ?targetName""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?drugName ?targetName ?actionType\nWHERE {\n  ?drug a chembl:SmallMolecule ;\n        rdfs:label ?drugName ;\n        chembl:highestDevelopmentPhase \""4\""^^<http://www.w3.org/2001/XMLSchema#integer> ;\n        chembl:hasMechanism ?mech .\n  \n  ?mech chembl:hasMechanismOfAction ?moa .\n  ?moa chembl:hasTarget ?target ;\n       chembl:actionType ?actionType .\n  \n  ?target rdfs:label ?targetName .\n  \n  FILTER(CONTAINS(LCASE(STR(?drugName)), \""tinib\"") && CONTAINS(LCASE(STR(?targetName)), \""kinase\""))\n}\nLIMIT 100""}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""imatinib"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""dasatinib"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""erlotinib"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""ibrutinib"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""ruxolitinib"", ""limit"": 5}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT ?drugName ?targetName ?actionType\nWHERE {\n  VALUES ?drug {\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL941>\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL1421>\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL553>\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL1873475>\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL1789941>\n  }\n  \n  ?drug rdfs:label ?drugName .\n  \n  ?drugIndication chembl:hasMolecule ?drug ;\n                  chembl:hasMechanism ?mech .\n  \n  ?mech chembl:hasMechanismOfAction ?moa .\n  ?moa chembl:hasTarget ?target ;\n       chembl:actionType ?actionType .\n  \n  ?target rdfs:label ?targetName .\n}\nLIMIT 200""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT ?drugName ?targetName ?actionType ?mechRef\nWHERE {\n  <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL941> rdfs:label ?drugName ;\n                                                             chembl:hasMechanism ?mechRef .\n  \n  ?mechRef chembl:hasMechanismOfAction ?moa .\n  \n  ?moa chembl:hasTarget ?target ;\n       chembl:actionType ?actionType .\n  \n  ?target rdfs:label ?targetName .\n}\nLIMIT 50""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT ?p ?o\nWHERE {\n  <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL941> ?p ?o .\n}\nLIMIT 100""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX cco: <http://rdf.ebi.ac.uk/terms/chembl#>\n\nSELECT DISTINCT ?drugName ?indication ?meshHeading ?mechRef\nWHERE {\n  VALUES ?drug {\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL941>\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL1421>\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL553>\n  }\n  \n  ?drug rdfs:label ?drugName .\n  \n  ?drugIndication chembl:hasMolecule ?drug .\n  \n  OPTIONAL { ?drugIndication chembl:hasIndication ?indication }\n  OPTIONAL { ?indication rdfs:label ?meshHeading }\n  OPTIONAL { ?drugIndication chembl:hasMechanism ?mechRef }\n}\nLIMIT 50""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?drugName ?targetName ?actionType\nWHERE {\n  VALUES ?molecule {\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL941>\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL1421>\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL553>\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL1873475>\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL1789941>\n  }\n  \n  ?molecule rdfs:label ?drugName .\n  \n  ?activity chembl:hasMolecule ?molecule ;\n            chembl:hasAssay ?assay ;\n            chembl:pChEMBL ?pchembl .\n  \n  ?assay chembl:hasTarget ?target .\n  ?target rdfs:label ?targetName .\n  \n  FILTER(CONTAINS(LCASE(?targetName), \""kinase\""))\n  FILTER(?pchembl > 7.0)\n}\nLIMIT 100""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?drugName ?targetName\nWHERE {\n  <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL941> rdfs:label ?drugName ;\n                                                              chembl:hasActivity ?activity .\n  \n  ?activity chembl:hasAssay ?assay .\n  ?assay chembl:hasTarget ?target .\n  ?target rdfs:label ?targetName .\n  \n  FILTER(CONTAINS(LCASE(?targetName), \""kinase\""))\n}\nLIMIT 20""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?drugName ?targetName\nWHERE {\n  VALUES ?drug {\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL941>\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL1421>\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL553>\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL1873475>\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL1789941>\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL2105759>\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL1173655>\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL2103875>\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL288441>\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL3286830>\n  }\n  \n  ?drug rdfs:label ?drugName ;\n        chembl:hasActivity ?activity .\n  \n  ?activity chembl:hasAssay ?assay .\n  ?assay chembl:hasTarget ?target .\n  ?target rdfs:label ?targetName .\n  \n  FILTER(CONTAINS(LCASE(?targetName), \""kinase\""))\n}\nORDER BY ?drugName ?targetName\nLIMIT 200""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?drugName (COUNT(DISTINCT ?target) as ?kinaseCount)\nWHERE {\n  ?drug rdfs:label ?drugName ;\n        chembl:highestDevelopmentPhase \""4\""^^<http://www.w3.org/2001/XMLSchema#integer> ;\n        chembl:hasActivity ?activity .\n  \n  ?activity chembl:hasAssay ?assay .\n  ?assay chembl:hasTarget ?target .\n  ?target rdfs:label ?targetName .\n  \n  FILTER(CONTAINS(LCASE(?targetName), \""kinase\""))\n  FILTER(CONTAINS(LCASE(?drugName), \""tinib\"") || \n         CONTAINS(LCASE(?drugName), \""imatinib\"") ||\n         CONTAINS(LCASE(?drugName), \""dasatinib\""))\n}\nGROUP BY ?drugName\nORDER BY DESC(?kinaseCount)\nLIMIT 50""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX skos: <http://www.w3.org/2004/02/skos/core#>\n\nSELECT DISTINCT ?drugName ?indicationLabel ?maxPhase\nWHERE {\n  VALUES ?drug {\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL941>\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL1421>\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL553>\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL1873475>\n    <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL1789941>\n  }\n  \n  ?drug rdfs:label ?drugName ;\n        chembl:highestDevelopmentPhase ?maxPhase .\n  \n  ?indication chembl:hasMolecule ?drug ;\n              rdfs:label ?indicationLabel .\n}\nLIMIT 50""}}]",VALUABLE,"Approved kinase inhibitors with DrugMechanism data such as IMATINIB, ERLOTINIB, SORAFENIB","COMPLEX QUERY requiring drug-target-mechanism knowledge.

Databases/Resources: ChEMBL

Knowledge Required:
- DrugMechanism entity for action type data
- Target filtering with bif:contains for 'kinase'
- highestDevelopmentPhase = 4 for marketed
- Join between molecule, target, and mechanism

Without proper knowledge: Cannot combine target text search with mechanism data.

Verified in chembl_exploration.md Pattern 5."
98,2026-02-01,Structured Query,What protein assemblies with specific oligomeric states are available in PDB?,True,True,True,0.6363636363636364,"Based on my training knowledge, the Protein Data Bank (PDB) contains numerous protein assemblies with various oligomeric states. Here are the main categories:

## Common Oligomeric States in PDB:

**Monomers**
- Single polypeptide chain structures
- Most abundant in the PDB

**Dimers**
- Homodimers (two identical subunits)
- Heterodimers (two different subunits)
- Very common functional state

**Trimers**
- Often found in viral proteins and some enzymes

**Tetramers**
- Frequently observed in enzymes and regulatory proteins
- Example: hemoglobin (α2β2 tetramer)

**Pentamers**
- Example: some ion channels and viral capsid proteins

**Hexamers**
- Common in enzymes like hexokinase
- Many AAA+ ATPases

**Higher-Order Oligomers**
- Octamers, decamers, dodecamers
- Large complexes like proteasomes (28-subunit)
- Viral capsids (60+ subunits in icosahedral viruses)

**Filamentous/Polymeric Assemblies**
- Actin filaments
- Microtubules
- Amyloid fibrils

## Special Features:

The PDB provides **biological assembly** files that represent the functional oligomeric state, which may differ from the asymmetric unit in the crystal structure. These assemblies are determined using:
- Crystallographic symmetry
- Interface analysis
- Experimental data

To find specific oligomeric states, you would typically search the PDB using their web interface with filters for quaternary structure or number of chains.",,,10.525215864181519,53,400,True,True,0.6363636363636364,"Based on my search of the Protein Data Bank (PDB), there are **extensive collections of protein assemblies with specific oligomeric states** available. Here's what I found:

## Overview of Available Oligomeric States in PDB:

### **General Oligomeric Assemblies** (3,661+ entries)
The PDB contains thousands of structures showing various oligomeric states with notable examples:

### **Dimers** (4,748+ entries)
- **4DMD**: GCN4 leucine zipper domain in dimeric state
- **8XUO**: Cryo-EM structure of tomato NRC2 dimer
- **2MJ2**: JC virus agnoprotein dimerization domain
- **2L9H**: Chemokine CCL5/RANTES oligomeric structure

### **Trimers**
- **4DME**: GCN4 leucine zipper domain in trimeric state

### **Tetramers** (2,350+ entries)
- **4JKT**: Mouse Glutaminase C (tetramer)
- **3VGT/3VGV/3VGU**: Nucleoside diphosphate kinase from Halomonas sp.
- **9BHG**: PRMT1 tetramer
- **9BW9**: Tetrameric HIV-1 integrase complex

### **Hexamers** (1,347+ entries)
- **6L8D**: Magnesium chelatase ATPase subunit
- **9BH4**: PRMT1 hexamer
- **8F6R**: Designed modular protein oligomer C6-79
- **5ZFU/5ZFP**: ExbB/ExbD hexameric complex
- **8RWY**: DtpB hexamer from Streptomyces lividans
- **7BAT**: Hexameric barrel state of de novo coiled-coil assembly

### **Heptamers**
- **7BAW**: Heptameric barrel state of de novo coiled-coil assembly

### **Higher Order Assemblies**
- **3ZZL**: TRAP (trp RNA-binding attenuation protein) - 12-subunit assembly
- **6S6U/6S6S/6S6T/6S6X**: Glutamate synthase in various oligomeric states (α4β3, α4β4, α6β4, α6β6)

The PDB contains rich structural information about protein oligomerization, ranging from simple dimers to complex multi-subunit assemblies, including both naturally occurring proteins and designed systems.",,,,28.61385703086853,16,1058,2791,79476,"mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity","[{""name"": ""mcp__togomcp__search_pdb_entity"", ""input"": {""db"": ""pdb"", ""query"": ""oligomeric state assembly"", ""limit"": 20}}, {""name"": ""mcp__togomcp__search_pdb_entity"", ""input"": {""db"": ""pdb"", ""query"": ""dimer oligomer"", ""limit"": 10}}, {""name"": ""mcp__togomcp__search_pdb_entity"", ""input"": {""db"": ""pdb"", ""query"": ""tetramer oligomer"", ""limit"": 10}}, {""name"": ""mcp__togomcp__search_pdb_entity"", ""input"": {""db"": ""pdb"", ""query"": ""hexamer oligomer"", ""limit"": 10}}]",VALUABLE,"Tetrameric, hexameric, and other oligomeric protein complexes including various enzymes and regulatory proteins","COMPLEX QUERY requiring assembly category knowledge.

Databases/Resources: PDB

Knowledge Required:
- pdbx_struct_assembly category for biological assembly info
- oligomeric_count and oligomeric_details properties
- struct category for entry identification
- CONTAINS filter for oligomeric state keyword

Without proper knowledge: Cannot navigate assembly metadata structure.

Verified in pdb_exploration.md Pattern 7."
99,2026-02-01,Integration,What gene functions are associated with the insulin signaling pathway?,True,True,True,0.5714285714285714,"The insulin signaling pathway involves numerous genes with diverse functions. Here are the key functional categories and associated genes:

## Core Insulin Signaling Components

**Insulin Receptor and Immediate Effectors:**
- **INSR** - insulin receptor (tyrosine kinase activity)
- **IRS1, IRS2, IRS4** - insulin receptor substrates (signal transduction)
- **PIK3CA, PIK3CB, PIK3R1** - phosphoinositide 3-kinase subunits (lipid kinase activity)

## Downstream Signaling Functions

**Kinase Cascade:**
- **AKT1, AKT2, AKT3** - protein kinase B (serine/threonine kinase, central node)
- **PDK1** - phosphoinositide-dependent kinase (activates AKT)
- **MTOR** - mechanistic target of rapamycin (growth regulation)
- **GSK3A, GSK3B** - glycogen synthase kinase 3 (metabolism regulation)

**Glucose Metabolism:**
- **SLC2A4 (GLUT4)** - glucose transporter (glucose uptake)
- **GYS1, GYS2** - glycogen synthase (glycogen synthesis)
- **PCK1, PCK2** - phosphoenolpyruvate carboxykinase (gluconeogenesis)
- **G6PC** - glucose-6-phosphatase (glucose production)

**Lipid Metabolism:**
- **FOXO1, FOXO3** - forkhead transcription factors (metabolic regulation)
- **SREBF1** - sterol regulatory element-binding protein (lipogenesis)

**Negative Regulators:**
- **PTEN** - phosphatase (opposes PI3K)
- **PTPN1** - protein tyrosine phosphatase (dephosphorylates insulin receptor)

These genes collectively regulate glucose homeostasis, protein synthesis, cell growth, and metabolic processes.",,,9.478571891784668,49,483,True,True,1.0,"Based on my comprehensive search of biological databases, I can provide you with detailed information about gene functions associated with the insulin signaling pathway.

## Overview of the Insulin Signaling Pathway

The insulin signaling pathway is a critical cellular signaling system that regulates glucose and energy homeostasis. It plays essential roles in:
- Carbohydrate and fat metabolism
- Glucose absorption in insulin-sensitive tissues (skeletal muscle and adipocytes)
- Cell growth and proliferation
- Gene transcription regulation

## Key Genes and Their Functions

Here are the major genes involved in the insulin signaling pathway, organized by their functional roles:

### **1. Receptor and Ligand**
- **INS** (Insulin) - The peptide hormone ligand that initiates the signaling cascade
- **INSR** (Insulin Receptor) - Cell surface receptor tyrosine kinase that binds insulin and undergoes autophosphorylation
- **IGF1R** (Insulin-like Growth Factor 1 Receptor) - Related receptor involved in growth signaling
- **IGF2** (Insulin-like Growth Factor II) - Growth factor with insulin-like properties

### **2. Insulin Receptor Substrates (IRS)**
- **IRS1** (Insulin Receptor Substrate 1) - Primary adaptor protein phosphorylated by INSR
- **IRS2** (Insulin Receptor Substrate 2) - Secondary adaptor protein with tissue-specific roles
- **IRS4** (Insulin Receptor Substrate 4) - Additional substrate with specialized functions

### **3. PI3K Pathway (Metabolic Effects)**
- **PIK3CA** (PI3K Catalytic Subunit Alpha) - Generates PIP3 second messenger
- **PIK3R1** (PI3K Regulatory Subunit Alpha) - Regulatory subunit of PI3K
- **PIK3R2** (PI3K Regulatory Subunit Beta) - Alternative regulatory subunit
- **PIK3R3** (PI3K Regulatory Subunit Gamma) - Another regulatory subunit
- **PIK3C2A** (Class II PI3K) - Involved in vesicle trafficking and glucose transport
- **PDPK1** (PDK1) - Phosphoinositide-dependent kinase that activates AKT
- **AKT1** (RAC-alpha) - Key serine/threonine kinase mediating metabolic effects
- **AKT2** (RAC-beta) - Primary AKT isoform in insulin-responsive tissues

### **4. MAPK Pathway (Growth and Proliferation)**
- **GRB2** (Growth Factor Receptor-Bound Protein 2) - Adaptor protein linking receptor to RAS
- **SHC1** (SHC-Transforming Protein 1) - Adaptor protein in MAPK activation
- **SOS1** (Son of Sevenless 1) - Guanine nucleotide exchange factor for RAS
- **SOS2** (Son of Sevenless 2) - Alternative GEF for RAS activation
- **HRAS** (GTPase HRas) - Small GTPase in MAPK cascade
- **RAF1** (RAF Proto-oncogene) - Serine/threonine kinase in MAPK pathway
- **MAPK1** (ERK2) - Mitogen-activated protein kinase
- **MAPK3** (ERK1) - Related MAPK for gene transcription

### **5. Downstream Metabolic Regulators**
- **GSK3A** (Glycogen Synthase Kinase-3 Alpha) - Regulates glycogen synthesis
- **GSK3B** (Glycogen Synthase Kinase-3 Beta) - Inhibited by AKT, promotes glycogen storage
- **FOXO1** (Forkhead Box Protein O1) - Transcription factor regulating glucose production
- **FOXO4** (Forkhead Box Protein O4) - Related transcription factor
- **SREBF1** (SREBP1) - Transcription factor for lipid synthesis genes
- **PDK2, PDK4** (Pyruvate Dehydrogenase Kinases) - Regulate glucose oxidation

### **6. Negative Regulators**
- **PTPN1** (PTP1B) - Protein tyrosine phosphatase that dephosphorylates INSR
- **PTPN2** (TCPTP) - Another phosphatase regulating insulin signaling
- **PTPRA** (Receptor Protein Tyrosine Phosphatase Alpha) - Membrane phosphatase
- **GRB10** (Growth Factor Receptor-Bound Protein 10) - Negative regulator of receptor
- **GRB14** (Growth Factor Receptor-Bound Protein 14) - Another inhibitory adaptor

### **7. Other Important Components**
- **GAB1** (GRB2-Associated Binding Protein 1) - Scaffolding protein
- **SH2B2** (SH2B Adapter Protein 2) - Enhances receptor signaling
- **SORBS1** (Sorbin and SH3 Domain Protein) - Cytoskeletal adaptor
- **CAV2** (Caveolin-2) - Membrane protein affecting receptor localization
- **IDE** (Insulin-Degrading Enzyme) - Degrades insulin to terminate signaling

## Major Biological Processes

The insulin signaling pathway regulates multiple processes:

1. **Glucose uptake and metabolism** - Through GLUT4 translocation to cell membrane
2. **Glycogen synthesis** - Via GSK3 inhibition
3. **Lipid synthesis** - Through SREBP1 activation
4. **Protein synthesis** - Via mTOR pathway activation
5. **Cell growth and survival** - Through AKT-mediated pathways
6. **Gene transcription** - Via FOXO and other transcription factors
7. **Autophagy regulation** - Through various kinase cascades

## Clinical Significance

Dysregulation of this pathway is associated with:
- Type 2 diabetes mellitus
- Metabolic syndrome
- Cancer (through growth signaling)
- Aging and longevity (particularly through FOXO factors)

This represents one of the most thoroughly studied signaling pathways in molecular biology, with over 70+ genes directly involved in its regulation and execution.",,,,90.84163117408752,35,3772,45355,292909,"mcp__ols__searchClasses, mcp__togomcp__search_reactome_entity, mcp__togomcp__run_sparql, mcp__ols__fetch, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__pubmed__search_articles, mcp__togomcp__run_sparql, mcp__ols__searchClasses, mcp__ols__getDescendants","[{""name"": ""mcp__ols__searchClasses"", ""input"": {""query"": ""insulin signaling pathway"", ""pageSize"": 20}}, {""name"": ""mcp__togomcp__search_reactome_entity"", ""input"": {""query"": ""insulin signaling pathway"", ""rows"": 30}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""reactome"", ""sparql_query"": ""PREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX biopax3: <http://www.biopax.org/release/biopax-level3.owl#>\n\nSELECT DISTINCT ?protein ?name ?gene WHERE {\n  <http://www.reactome.org/biopax/74/74752#Pathway3> biopax3:pathwayComponent ?component .\n  ?component biopax3:participant ?participant .\n  ?participant biopax3:entityReference ?reference .\n  ?reference biopax3:name ?name .\n  OPTIONAL { ?reference biopax3:xref ?xref .\n             ?xref biopax3:db \""UniProt\"" .\n             ?xref biopax3:id ?protein }\n  OPTIONAL { ?reference biopax3:xref ?gxref .\n             ?gxref biopax3:db \""NCBI Gene\"" .\n             ?gxref biopax3:id ?gene }\n} LIMIT 100""}}, {""name"": ""mcp__ols__fetch"", ""input"": {""id"": ""go+http://purl.obolibrary.org/obo/GO_0008286""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""PREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX up: <http://purl.uniprot.org/core/>\n\nSELECT DISTINCT ?protein ?geneName ?goTerm ?functionLabel WHERE {\n  ?protein a up:Protein ;\n           up:organism <http://purl.uniprot.org/taxonomy/9606> ;\n           up:classifiedWith <http://purl.obolibrary.org/obo/GO_0008286> ;\n           up:encodedBy ?gene .\n  ?gene skos:prefLabel ?geneName .\n  \n  OPTIONAL {\n    ?protein up:classifiedWith ?goTerm .\n    ?goTerm rdfs:label ?functionLabel .\n    FILTER(CONTAINS(STR(?goTerm), \""GO_\""))\n  }\n} LIMIT 50""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""PREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX up: <http://purl.uniprot.org/core/>\n\nSELECT DISTINCT ?geneName ?proteinName WHERE {\n  ?protein a up:Protein ;\n           up:organism <http://purl.uniprot.org/taxonomy/9606> ;\n           up:classifiedWith <http://purl.obolibrary.org/obo/GO_0008286> ;\n           up:encodedBy ?gene ;\n           up:recommendedName ?recName .\n  ?gene skos:prefLabel ?geneName .\n  ?recName up:fullName ?proteinName .\n} ORDER BY ?geneName""}}, {""name"": ""mcp__pubmed__search_articles"", ""input"": {""query"": ""insulin signaling pathway gene function review"", ""max_results"": 5, ""sort"": ""relevance""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""PREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX up: <http://purl.uniprot.org/core/>\n\nSELECT DISTINCT ?geneName ?functionType ?functionLabel WHERE {\n  VALUES ?gene { \""AKT1\"" \""AKT2\"" \""IRS1\"" \""IRS2\"" \""INSR\"" \""PIK3CA\"" \""PIK3R1\"" \""GRB2\"" \""SHC1\"" \""FOXO1\"" \""GSK3B\"" \""MAPK1\"" \""PDPK1\"" \""PTPN1\"" \""SOS1\"" \""GRB10\"" \""INS\"" \""IGF1R\"" }\n  ?protein a up:Protein ;\n           up:organism <http://purl.uniprot.org/taxonomy/9606> ;\n           up:encodedBy ?geneNode .\n  ?geneNode skos:prefLabel ?geneName .\n  FILTER(?geneName IN (\""AKT1\"", \""AKT2\"", \""IRS1\"", \""IRS2\"", \""INSR\"", \""PIK3CA\"", \""PIK3R1\"", \""GRB2\"", \""SHC1\"", \""FOXO1\"", \""GSK3B\"", \""MAPK1\"", \""PDPK1\"", \""PTPN1\"", \""SOS1\"", \""GRB10\"", \""INS\"", \""IGF1R\""))\n  \n  ?protein up:classifiedWith ?goTerm .\n  ?goTerm rdfs:label ?functionLabel .\n  \n  ?goTerm rdf:type ?goType .\n  BIND(\n    IF(CONTAINS(STR(?goType), \""Molecular_Function\""), \""Molecular Function\"",\n    IF(CONTAINS(STR(?goType), \""Biological_Process\""), \""Biological Process\"",\n    IF(CONTAINS(STR(?goType), \""Cellular_Component\""), \""Cellular Component\"", \""Other\""))) AS ?functionType\n  )\n  \n  FILTER(?functionType != \""Other\"" && CONTAINS(STR(?goTerm), \""GO_\""))\n} ORDER BY ?geneName ?functionType""}}, {""name"": ""mcp__ols__searchClasses"", ""input"": {""query"": ""insulin receptor signaling pathway biological process"", ""ontologyId"": ""go"", ""pageSize"": 30}}, {""name"": ""mcp__ols__getDescendants"", ""input"": {""ontologyId"": ""go"", ""classIri"": ""http://purl.obolibrary.org/obo/GO_0008286"", ""pageSize"": 50}}]",VALUABLE,GO molecular functions and biological processes related to insulin signaling,"COMPLEX QUERY requiring pathway-GO integration.

Databases/Resources: GO, MeSH (or Reactome)

Knowledge Required:
- bif:contains for 'insulin' keyword matching
- Cross-database query on primary endpoint
- Namespace filtering with STR()
- FROM clause for consistent results

Without proper knowledge: Cannot cross-reference insulin-related terms effectively.

Verified in go_exploration.md Pattern 4."
100,2026-02-01,Integration,What is the Gene Ontology term for 'apoptosis'?,True,True,False,0.3333333333333333,"The Gene Ontology term for 'apoptosis' is **GO:0006915**.

This term is defined as ""A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies.""

GO:0006915 falls under the Biological Process ontology in the Gene Ontology classification system.",,,5.932439088821411,53,190,True,False,0.3333333333333333,"Perfect! The Gene Ontology term for **apoptosis** is:

**GO:0006915 - apoptotic process**

**Definition:** A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died.

This is the primary GO term used to describe the biological process of apoptosis, also known as programmed cell death.",,,,25.73885202407837,18,495,10988,116687,"mcp__ols__search, mcp__ols__searchClasses, mcp__ols__fetch","[{""name"": ""mcp__ols__search"", ""input"": {""query"": ""apoptosis""}}, {""name"": ""mcp__ols__searchClasses"", ""input"": {""query"": ""apoptosis"", ""ontologyId"": ""go""}}, {""name"": ""mcp__ols__fetch"", ""input"": {""id"": ""go+http://purl.obolibrary.org/obo/GO_0006915""}}]",VALUABLE,GO:0006915 (apoptotic process),"SIMPLE QUERY - Straightforward ontology lookup.

Method: OLS4 searchClasses for 'apoptosis' in GO

Demonstrates when basic ontology search tools suffice.

Verified through OLS4 search capabilities."
101,2026-02-01,Completeness,What fraction of PDB structures have associated publication records with PubMed IDs?,True,False,True,0.5,"I don't have access to current, precise statistics about what fraction of PDB structures have associated PubMed IDs. However, I can provide some general context based on my training knowledge:

**General observations:**

1. **The vast majority** of PDB entries have associated publications with PubMed IDs - typically well over 80-90% of structures.

2. **Primary citations** are strongly encouraged (essentially required) for PDB deposition, and most of these are journal articles that receive PubMed IDs.

3. **Structures without PubMed IDs** typically include:
   - Very recent depositions where papers are still in preparation or under review
   - Structures from structural genomics initiatives that may be published in bulk
   - Some older entries deposited before current citation requirements
   - Unpublished structures (though these are relatively rare)

4. The PDB has become increasingly stringent about requiring proper citation information over time.

**For an exact current percentage**, you would need to query the PDB database directly or consult their latest statistics reports, as this number changes as new structures are deposited and publications are linked to existing entries.

If you need the precise current fraction, I'd recommend checking the PDB's official statistics pages or performing a direct database query.",,,9.146340131759644,55,284,True,True,0.625,"Perfect! Now I have all the data I need to answer your question.

## Answer

Based on my analysis of the PDB RDF database:

- **Total PDB structures**: 245,833
- **Structures with PubMed IDs**: 169,057
- **Fraction with PubMed IDs**: **68.8%** (169,057 / 245,833)

This means that approximately **69% of PDB structures** have associated publication records with PubMed IDs. 

The remaining ~31% of structures either:
1. Have citations to publications not indexed in PubMed (e.g., books, unpublished data, patents)
2. Were deposited without primary publication citations
3. Have citations pending publication

It's worth noting that the PDB actually contains 247,556 total citation records, but many structures have multiple citations (primary publications, related papers, methods papers, etc.). Of these citations, 181,261 (73.2%) have PubMed IDs.",,,,135.56934309005737,53,5076,10343,613367,"mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql","[{""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""\nPREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX pdbo: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\n\nSELECT \n  (COUNT(DISTINCT ?entry) AS ?total_entries)\n  (COUNT(DISTINCT ?entry_with_pmid) AS ?entries_with_pmid)\nWHERE {\n  ?entry rdf:type pdbo:datablock .\n  \n  OPTIONAL {\n    ?entry pdbo:has_citation ?citation .\n    ?citation pdbo:citation.pdbx_database_id_PubMed ?pmid .\n    BIND(?entry AS ?entry_with_pmid)\n  }\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""\nPREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX pdbo: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\n\nSELECT \n  (COUNT(DISTINCT ?entry) AS ?total)\n  (COUNT(DISTINCT ?pmid) AS ?with_pmid)\nWHERE {\n  ?entry rdf:type pdbo:datablock .\n  OPTIONAL {\n    ?entry pdbo:has_citation ?citation .\n    ?citation pdbo:citation.pdbx_database_id_PubMed ?pmid .\n    FILTER(BOUND(?pmid))\n  }\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""\nPREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX pdbo: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\n\nSELECT DISTINCT ?prop\nWHERE {\n  ?entry rdf:type pdbo:datablock .\n  ?entry pdbo:has_citation ?citation .\n  ?citation ?prop ?value .\n  FILTER(CONTAINS(str(?prop), \""pubmed\"") || CONTAINS(str(?prop), \""PubMed\""))\n}\nLIMIT 10\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""\nPREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX pdbo: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\n\nSELECT DISTINCT ?prop\nWHERE {\n  ?entry rdf:type pdbo:datablock .\n  ?entry pdbo:has_citation ?citation .\n  ?citation ?prop ?value .\n}\nLIMIT 50\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""\nPREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX pdbo: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\n\nSELECT ?total ?with_pmid\nWHERE {\n  {\n    SELECT (COUNT(DISTINCT ?entry) AS ?total)\n    WHERE {\n      ?entry rdf:type pdbo:datablock .\n    }\n  }\n  {\n    SELECT (COUNT(DISTINCT ?entry) AS ?with_pmid)\n    WHERE {\n      ?entry rdf:type pdbo:datablock .\n      ?entry pdbo:has_database_2Category ?dbref .\n      ?dbref pdbo:database_2.database_id \""PubMed\"" .\n    }\n  }\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""\nPREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX pdbo: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\nPREFIX dcterms: <http://purl.org/dc/terms/>\n\nSELECT (COUNT(DISTINCT ?entry) AS ?total_entries)\n       (COUNT(DISTINCT ?entry_with_ref) AS ?entries_with_pubmed)\nWHERE {\n  ?entry rdf:type pdbo:datablock .\n  \n  OPTIONAL {\n    ?entry dcterms:references ?ref .\n    FILTER(CONTAINS(str(?ref), \""pubmed\""))\n    BIND(?entry AS ?entry_with_ref)\n  }\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""\nPREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX pdbo: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\n\nSELECT ?s ?p ?o\nWHERE {\n  ?s ?p ?o .\n  FILTER(CONTAINS(str(?o), \""pubmed\"") || CONTAINS(str(?o), \""PubMed\""))\n}\nLIMIT 20\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""\nPREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX pdbo: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\n\nSELECT (COUNT(*) AS ?count)\nWHERE {\n  ?entry rdf:type pdbo:datablock .\n  ?entry pdbo:has_citationCategory ?citation .\n  ?citation pdbo:citation.pdbx_database_id_PubMed ?pmid .\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""\nPREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX owl: <http://www.w3.org/2002/07/owl#>\n\nSELECT DISTINCT ?property\nWHERE {\n  ?property rdfs:domain ?domain .\n  FILTER(CONTAINS(str(?property), \""citation\"") || CONTAINS(str(?property), \""Citation\""))\n}\nLIMIT 100\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""\nPREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?property\nWHERE {\n  ?property rdf:type owl:DatatypeProperty .\n  FILTER(CONTAINS(str(?property), \""pubmed\"") || CONTAINS(str(?property), \""PubMed\""))\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""\nPREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX pdbo: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\n\nSELECT (COUNT(DISTINCT ?entry) AS ?total_entries)\n       (COUNT(DISTINCT ?entry_with_pmid) AS ?entries_with_pmid)\nWHERE {\n  ?entry rdf:type pdbo:datablock .\n  \n  OPTIONAL {\n    ?entry pdbo:has_citation ?citation .\n    ?citation pdbo:citation.pdbx_database_id_PubMed ?pmid .\n    FILTER(BOUND(?pmid))\n    BIND(?entry AS ?entry_with_pmid)\n  }\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""\nPREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX pdbo: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\n\nSELECT (COUNT(DISTINCT ?entry) AS ?total)\n       (COUNT(?citation) AS ?total_citations)\n       (COUNT(?pmid) AS ?pmids)\nWHERE {\n  ?entry rdf:type pdbo:datablock .\n  ?entry pdbo:has_citation ?citation .\n  OPTIONAL {\n    ?citation pdbo:citation.pdbx_database_id_PubMed ?pmid .\n  }\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""\nPREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX pdbo: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\n\nSELECT (COUNT(*) AS ?count)\nWHERE {\n  ?citation rdf:type pdbo:citation .\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""\nPREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX pdbo: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\n\nSELECT (COUNT(DISTINCT ?citation) AS ?total_citations)\n       (COUNT(DISTINCT ?pmid_citation) AS ?citations_with_pmid)\nWHERE {\n  ?citation rdf:type pdbo:citation .\n  \n  OPTIONAL {\n    ?citation pdbo:citation.pdbx_database_id_PubMed ?pmid .\n    BIND(?citation AS ?pmid_citation)\n  }\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""\nPREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX pdbo: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\n\nSELECT (COUNT(DISTINCT ?entry) AS ?total_entries)\n       (COUNT(DISTINCT ?entry_with_pmid) AS ?entries_with_pmid)\nWHERE {\n  ?entry rdf:type pdbo:datablock .\n  \n  OPTIONAL {\n    ?citation pdbo:reference_to_citation ?entry .\n    ?citation pdbo:citation.pdbx_database_id_PubMed ?pmid .\n    BIND(?entry AS ?entry_with_pmid)\n  }\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""\nPREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX pdbo: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\n\nSELECT DISTINCT ?prop\nWHERE {\n  ?citation rdf:type pdbo:citation .\n  ?citation ?prop ?value .\n}\nLIMIT 30\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""\nPREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX pdbo: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\n\nSELECT (COUNT(DISTINCT ?entry) AS ?total_entries)\n       (COUNT(DISTINCT ?entry_with_pmid) AS ?entries_with_pmid)\nWHERE {\n  ?entry rdf:type pdbo:datablock .\n  \n  OPTIONAL {\n    ?citation rdf:type pdbo:citation .\n    ?citation pdbo:of_datablock ?entry .\n    ?citation pdbo:citation.pdbx_database_id_PubMed ?pmid .\n    BIND(?entry AS ?entry_with_pmid)\n  }\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""\nPREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX pdbo: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\n\nSELECT (COUNT(DISTINCT ?entry) AS ?entries_with_pmid)\nWHERE {\n  ?citation rdf:type pdbo:citation .\n  ?citation pdbo:of_datablock ?entry .\n  ?citation pdbo:citation.pdbx_database_id_PubMed ?pmid .\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""\nPREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX pdbo: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\n\nSELECT (COUNT(DISTINCT ?entry) AS ?total_entries)\nWHERE {\n  ?entry rdf:type pdbo:datablock .\n}\n""}}]",CRITICAL,"Approximately 69% (169,057 entries with PubMed citations out of ~245,000 total)","COMPLEX QUERY requiring citation coverage calculation.

Databases/Resources: PDB

Knowledge Required:
- citation category for publication data
- pdbx_database_id_PubMed property
- COUNT for coverage calculation
- FROM graph clause

Without proper knowledge: Cannot identify citation coverage correctly.

Verified in pdb_exploration.md Pattern 10."
102,2026-02-01,Completeness,How many UniProt cross-references exist across all PDB structures?,True,False,False,0.2857142857142857,"I don't have access to current, exact statistics on the total number of UniProt cross-references across all PDB structures.

However, I can provide some context:

- The vast majority of PDB structures contain protein molecules that have UniProt cross-references, as UniProt is the primary database for protein sequences
- A single PDB structure can have multiple UniProt cross-references if it contains multiple protein chains or different proteins
- As of my knowledge cutoff, the PDB contained over 200,000 structures, and most would have at least one UniProt cross-reference

To get the exact current number, you would need to:
1. Query the PDB database directly (via their API or website)
2. Use the PDBe (Protein Data Bank in Europe) REST API which provides cross-reference statistics
3. Access the wwPDB FTP site where such mapping files are maintained

The actual number would be in the hundreds of thousands to millions of cross-references, but I cannot provide a precise figure without accessing current database statistics.",,,6.999801874160767,52,231,True,False,0.2857142857142857,"Perfect! Based on my query of the PDB database, here are the statistics for UniProt cross-references:

## UniProt Cross-References in PDB Structures

- **Total UniProt cross-references**: 352,092
- **Unique UniProt entries referenced**: 66,565
- **PDB entries with UniProt cross-references**: 64,444

This means that across all PDB structures, there are approximately **352,000 individual cross-reference links** to UniProt, representing about **66,500 distinct UniProt protein entries**. These cross-references are found in over **64,000 PDB entries**, which represents a significant portion of the PDB database showing the strong connection between protein structures and their corresponding UniProt sequence records.",,,,67.0539960861206,49,1819,3055,244621,"mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql","[{""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""\nPREFIX pdbx: <http://pdbj.org/schema/pdbx-v50.owl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT (COUNT(DISTINCT ?uniprot) AS ?count)\nWHERE {\n  ?entry a pdbx:datablock ;\n         pdbx:has_struct_refContent ?struct_ref .\n  ?struct_ref pdbx:struct_ref.db_name \""UNP\"" ;\n              pdbx:struct_ref.db_code ?uniprot .\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""\nPREFIX pdbx: <http://pdbj.org/schema/pdbx-v50.owl#>\nPREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\n\nSELECT (COUNT(*) AS ?count)\nWHERE {\n  ?ref pdbx:reference_database_name \""UNP\"" .\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""\nPREFIX pdbx: <http://pdbj.org/schema/pdbx-v50.owl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?predicate\nWHERE {\n  ?s ?predicate ?o .\n  FILTER(CONTAINS(STR(?predicate), \""uniprot\"") || CONTAINS(STR(?predicate), \""UNP\"") || CONTAINS(STR(?predicate), \""db\""))\n}\nLIMIT 100\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""\nPREFIX pdbx: <http://pdbj.org/schema/pdbx-v50.owl#>\n\nSELECT (COUNT(*) AS ?count)\nWHERE {\n  ?s ?p ?o .\n  FILTER(CONTAINS(STR(?o), \""uniprot\""))\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""\nPREFIX pdbx: <http://pdbj.org/schema/pdbx-v50.owl#>\nPREFIX pdbo: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\n\nSELECT (COUNT(DISTINCT ?uniprot_id) AS ?count)\nWHERE {\n  ?entity pdbo:reference_to_uniprot ?uniprot .\n  ?uniprot pdbo:db_accession ?uniprot_id .\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""\nSELECT DISTINCT ?type\nWHERE {\n  ?s a ?type .\n}\nLIMIT 20\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""\nPREFIX pdbo: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\n\nSELECT (COUNT(DISTINCT ?uniprot_id) AS ?count)\nWHERE {\n  ?ref pdbo:struct_ref.db_name \""UNP\"" ;\n       pdbo:struct_ref.db_code ?uniprot_id .\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""\nPREFIX pdbo: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\n\nSELECT (COUNT(*) AS ?total_references) (COUNT(DISTINCT ?uniprot_id) AS ?unique_uniprots) (COUNT(DISTINCT ?pdb_entry) AS ?pdb_entries_with_uniprot)\nWHERE {\n  ?ref pdbo:struct_ref.db_name \""UNP\"" ;\n       pdbo:struct_ref.db_code ?uniprot_id ;\n       pdbo:struct_ref.pdbx_db_accession ?pdb_entry .\n}\n""}}]",CRITICAL,"352,000+ UniProt references (~1.72 per entry due to multi-chain structures)","COMPLEX QUERY requiring cross-reference aggregation.

Databases/Resources: PDB

Knowledge Required:
- struct_ref category for cross-references
- db_name = 'UNP' filter for UniProt
- COUNT aggregation
- Understanding of multi-chain structure implications

Without proper knowledge: Cannot navigate cross-reference structure.

Verified in pdb_exploration.md Pattern 2."
103,2026-02-01,Specificity,What gene types are represented in ClinVar's gene database and how do they link to NCBI Gene?,True,True,True,0.9,"Based on my training knowledge, ClinVar's gene database represents various gene types and maintains strong connections to NCBI Gene:

## Gene Types in ClinVar

ClinVar includes multiple gene types, primarily:

1. **Protein-coding genes** - The most abundant type, representing genes that encode proteins
2. **Non-coding RNA genes** - Including:
   - microRNA (miRNA) genes
   - Long non-coding RNA (lncRNA) genes
   - Small nuclear RNA (snRNA) genes
   - Transfer RNA (tRNA) genes
3. **Pseudogenes** - Non-functional gene copies
4. **Other gene types** - Various specialized categories as defined by NCBI Gene

## Linkage to NCBI Gene

ClinVar links to NCBI Gene through:

1. **Gene IDs** - Each gene in ClinVar is linked using NCBI's official Gene ID (a unique numerical identifier)

2. **Gene symbols** - ClinVar uses HGNC-approved gene symbols (for human genes) that correspond to those in NCBI Gene

3. **Cross-references** - ClinVar records include direct cross-references to NCBI Gene entries, allowing users to access:
   - Comprehensive gene information
   - Genomic coordinates
   - Gene function and expression data
   - Additional external database links

4. **Annotation consistency** - ClinVar relies on NCBI Gene for standardized gene nomenclature and classification

This integration ensures that variant-gene associations in ClinVar are connected to the authoritative gene information maintained by NCBI Gene, facilitating comprehensive genetic variant interpretation.",,,8.249752759933472,60,369,True,True,1.0,"Perfect! Now I have comprehensive information. Let me compile the answer based on the data I've gathered.

## Gene Types in ClinVar and Their Connection to NCBI Gene

Based on my exploration of ClinVar and NCBI Gene databases, here's what I found:

### Gene Types in NCBI Gene Database

The **NCBI Gene** database contains genes classified into several types, including:

1. **Protein-coding genes** - Genes that encode proteins (like BRCA1, which I examined as an example)
2. **ncRNA genes** (non-coding RNA) - Including various subtypes:
   - rRNA (ribosomal RNA)
   - tRNA (transfer RNA)
   - miRNA (microRNA)
   - lncRNA (long non-coding RNA)
   - snRNA (small nuclear RNA)
   - snoRNA (small nucleolar RNA)
   - scRNA (small cytoplasmic RNA)
   - miscRNA (miscellaneous RNA)
3. **Pseudogenes** - Non-functional gene copies
4. **Biological regions** - Regulatory or structural genomic regions
5. **Other** and **unknown** classifications

According to the TogoID dataset configuration, NCBI Gene includes annotation filters for these types: `protein-coding, ncRNA, pseudo, rRNA, tRNA, scRNA, snRNA, snoRNA, miscRNA, biological-region, unknown, other`.

### How ClinVar Links to NCBI Gene

**ClinVar variants connect to NCBI Gene through direct gene associations:**

1. **Relationship Type**: The TogoID system shows the relationship as:
   - **Forward**: ""is located in"" (TIO_000062) - ClinVar variants are located in genes
   - **Reverse**: ""has variant"" (TIO_000063) - Genes have ClinVar variants

2. **Linkage Mechanism**: Each ClinVar variant record includes:
   - **Gene symbol** (e.g., ""BRCA1"")
   - **NCBI Gene ID** (e.g., ""672"" for BRCA1)
   - **Strand information** (+ or -)
   - **Source** (submitted or annotated)

3. **Example**: In the BRCA1 variants I examined:
   - ClinVar variant VCV004686574 → links to → Gene symbol ""BRCA1"" → Gene ID ""672""
   - ClinVar variant VCV004686566 → links to → Gene symbol ""BRCA1"" → Gene ID ""672""

4. **ID Conversion**: The TogoID conversion service allows direct conversion between ClinVar IDs and NCBI Gene IDs, facilitating cross-database queries and integration.

### Practical Implications

This linkage enables researchers to:
- Find all genetic variants associated with a specific gene
- Identify which genes are affected by clinically significant variants
- Trace from variant-level data to comprehensive gene annotations including function, expression, pathways, and orthology
- Connect clinical genetics data (ClinVar) with comprehensive genomic annotations (NCBI Gene)

The integration represents a crucial bridge between clinical genomics and fundamental gene biology, supporting both research and clinical applications in precision medicine.",,,,113.6266040802002,48,3308,49250,257932,"mcp__togomcp__ncbi_esearch, mcp__togomcp__list_databases, mcp__togomcp__togoid_getRelation, mcp__togomcp__ncbi_esearch, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__get_graph_list, mcp__togomcp__ncbi_esummary, mcp__togomcp__togoid_convertId, mcp__togomcp__ncbi_esearch, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__ncbi_esummary, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_efetch, mcp__togomcp__togoid_getAllDataset, WebSearch","[{""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""clinvar"", ""query"": ""gene[Filter]"", ""max_results"": 50}}, {""name"": ""mcp__togomcp__list_databases"", ""input"": {}}, {""name"": ""mcp__togomcp__togoid_getRelation"", ""input"": {""source"": ""clinvar"", ""target"": ""ncbigene""}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""clinvar"", ""query"": ""BRCA1[gene]"", ""max_results"": 5}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""clinvar"", ""sparql_query"": ""PREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX clinvar: <http://purl.jp/bio/10/clinvar/>\n\nSELECT DISTINCT ?geneType (COUNT(?gene) as ?count)\nWHERE {\n  ?gene rdf:type clinvar:Gene .\n  ?gene clinvar:geneType ?geneType .\n}\nGROUP BY ?geneType\nORDER BY DESC(?count)\nLIMIT 50""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""clinvar"", ""sparql_query"": ""PREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX clinvar: <http://purl.jp/bio/clinvar/>\nPREFIX dcterms: <http://purl.org/dc/terms/>\n\nSELECT DISTINCT ?gene ?geneSymbol ?geneType ?ncbiGeneId\nWHERE {\n  ?gene rdf:type clinvar:Gene .\n  ?gene clinvar:geneSymbol ?geneSymbol .\n  ?gene clinvar:geneType ?geneType .\n  OPTIONAL { ?gene dcterms:identifier ?ncbiGeneId }\n}\nLIMIT 20""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""clinvar"", ""sparql_query"": ""PREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\n\nSELECT DISTINCT ?class (COUNT(?instance) as ?count)\nWHERE {\n  ?instance rdf:type ?class .\n}\nGROUP BY ?class\nORDER BY DESC(?count)\nLIMIT 20""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""clinvar"", ""sparql_query"": ""PREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\n\nSELECT DISTINCT ?property (COUNT(*) as ?count)\nWHERE {\n  ?s ?property ?o .\n  FILTER(CONTAINS(STR(?property), \""gene\""))\n}\nGROUP BY ?property\nORDER BY DESC(?count)\nLIMIT 30""}}, {""name"": ""mcp__togomcp__get_graph_list"", ""input"": {""dbname"": ""clinvar""}}, {""name"": ""mcp__togomcp__ncbi_esummary"", ""input"": {""database"": ""clinvar"", ""ids"": [""4686574"", ""4686566""]}}, {""name"": ""mcp__togomcp__togoid_convertId"", ""input"": {""ids"": ""672"", ""route"": ""clinvar,ncbigene""}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""gene"", ""query"": ""BRCA1[Gene Name] AND Homo sapiens[Organism]"", ""max_results"": 1}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""ncbigene"", ""sparql_query"": ""PREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX ncbigene: <http://identifiers.org/ncbigene/>\nPREFIX dcterms: <http://purl.org/dc/terms/>\nPREFIX sio: <http://semanticscience.org/resource/>\n\nSELECT DISTINCT ?geneType (COUNT(?gene) as ?count)\nWHERE {\n  ?gene rdf:type ?geneType .\n  FILTER(CONTAINS(STR(?geneType), \""ncbigene\"") || CONTAINS(STR(?geneType), \""gene\""))\n}\nGROUP BY ?geneType\nORDER BY DESC(?count)\nLIMIT 30""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""ncbigene"", ""sparql_query"": ""PREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?property\nWHERE {\n  ?s ?property ?o .\n  FILTER(CONTAINS(STR(?property), \""type\""))\n}\nLIMIT 50""}}, {""name"": ""mcp__togomcp__ncbi_esummary"", ""input"": {""database"": ""gene"", ""ids"": [""672""]}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""gene"", ""query"": ""protein-coding[Gene Type] AND Homo sapiens[Organism]"", ""max_results"": 5}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""gene"", ""query"": ""ncRNA[Gene Type]"", ""max_results"": 1}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""gene"", ""query"": ""pseudogene[Gene Type]"", ""max_results"": 1}}, {""name"": ""mcp__togomcp__ncbi_efetch"", ""input"": {""database"": ""gene"", ""ids"": [""672"", ""220202"", ""28719420""], ""rettype"": ""docsum"", ""retmode"": ""xml""}}, {""name"": ""mcp__togomcp__togoid_getAllDataset"", ""input"": {}}, {""name"": ""WebSearch"", ""input"": {""query"": ""NCBI Gene database gene types categories 2026""}}]",VALUABLE,"Gene types including protein-coding, RNA genes, pseudogenes from NCBI Gene database","COMPLEX QUERY requiring gene entity knowledge.

Databases/Resources: ClinVar, NCBI Gene

Knowledge Required:
- Cross-database join between ClinVar and NCBI Gene
- Gene type property from NCBI Gene
- BIND for URI conversion
- VALUES pre-filtering for performance

Without proper knowledge: Cannot access gene type data across databases.

Verified in clinvar_exploration.md Pattern 1."
104,2026-02-01,Specificity,Is the Rhea reaction RHEA:10000 a transport reaction?,True,False,False,0.0,"I don't have specific information about RHEA:10000 in my training data. RHEA is the expert biochemical reaction database, and reactions are classified by type including transport reactions.

To determine if RHEA:10000 is a transport reaction, you would need to look up this specific reaction ID in the RHEA database. Transport reactions typically involve the movement of molecules across biological membranes without chemical transformation, and they would be annotated as such in RHEA.

I cannot answer with certainty whether RHEA:10000 is a transport reaction without access to the database.",,,4.462960720062256,54,131,True,False,0.0,"No, RHEA:10000 is **not a transport reaction**. 

This reaction is: **H2O + pentanamide = NH4(+) + pentanoate**

This is a hydrolysis reaction where pentanamide is broken down by water into ammonium ion and pentanoate. It's a chemical transformation reaction rather than a transport reaction (which would involve moving molecules across membranes or between compartments without chemical change).",,,,15.004117012023926,9,306,588,52265,mcp__togomcp__run_sparql,"[{""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""rhea"", ""sparql_query"": ""\nPREFIX rh: <http://rdf.rhea-db.org/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT ?equation ?isTransport\nWHERE {\n  rh:10000 rdfs:label ?equation .\n  OPTIONAL { rh:10000 rh:isTransport ?isTransport }\n}\n""}}]",CRITICAL,No (isTransport = 0 for RHEA:10000),"SIMPLE QUERY - Straightforward property lookup.

Method: Direct lookup of rhea:isTransport property

Demonstrates when basic property lookups suffice.

Verified in rhea_exploration.md simple queries section."
105,2026-02-01,Currency,What software tools are most commonly used for protein structure determination and refinement?,True,True,True,0.6666666666666666,"# Common Software Tools for Protein Structure Determination and Refinement

## Structure Determination

### X-ray Crystallography
- **PHENIX** - Comprehensive suite for automated and manual structure determination
- **CCP4** - Collection of programs for data processing, phasing, and refinement
- **XDS/XSCALE** - Data processing and scaling
- **HKL-2000/HKL-3000** - Data integration and processing
- **SHELX** - Phasing and refinement, especially for small molecules and experimental phasing
- **AutoSol/AutoBuild** (PHENIX) - Automated phasing and model building

### Cryo-EM
- **RELION** - Bayesian approach to particle refinement
- **cryoSPARC** - Fast processing with modern algorithms
- **cisTEM** - User-friendly interface for single particle analysis
- **EMAN2** - Single particle reconstruction
- **CryoLo** - Automated particle picking using deep learning

### NMR Spectroscopy
- **CYANA** - Automated structure calculation
- **XPLOR-NIH** - Structure determination with various restraints
- **ARIA** - Automated NOE assignment
- **NMRPipe** - Spectral processing

## Model Building
- **Coot** - Interactive graphics-based model building and validation
- **O** - Classic molecular graphics program
- **MAIN** - Model building and refinement

## Refinement
- **REFMAC5** (CCP4) - Maximum likelihood refinement
- **phenix.refine** - Comprehensive refinement with restraints
- **BUSTER** - Advanced refinement with restraint generation
- **CNS** - Crystallography and NMR system

## Validation
- **MolProbity** - Structure quality assessment
- **PROCHECK** - Stereochemical quality checks
- **WHATCHECK** - Structure validation
- **PDB-REDO** - Automated re-refinement and validation

Most modern workflows combine multiple tools from these suites.",,,11.579015016555786,52,489,True,True,0.5555555555555556,"I can help you with information about commonly used software tools for protein structure determination and refinement.

The field uses different tools depending on the experimental method:

## **X-ray Crystallography**

**Structure Determination:**
- **PHENIX** (Python-based Hierarchical ENvironment for Integrated Xtallography) - comprehensive suite for automated structure determination
- **CCP4** (Collaborative Computational Project Number 4) - extensive collection of programs for crystallographic computing
- **SHELX** - widely used for small molecule and macromolecular structure solution
- **AutoSHARP/autoSHARP** - automated structure solution pipeline

**Model Building:**
- **Coot** - interactive model-building and validation tool with graphical interface
- **PHENIX AutoBuild** - automated model building
- **Buccaneer** (CCP4) - automated protein model building
- **ARP/wARP** - automated model building and refinement

**Refinement:**
- **PHENIX.refine** - maximum likelihood refinement with advanced restraints
- **REFMAC5** (CCP4) - maximum likelihood refinement
- **BUSTER** - sophisticated refinement with advanced features
- **SHELXL** - least-squares refinement

## **Cryo-Electron Microscopy (Cryo-EM)**

**Image Processing & Map Generation:**
- **RELION** - Bayesian approach to refinement and classification
- **cryoSPARC** - faster processing with advanced algorithms
- **cisTEM** - user-friendly interface for single particle analysis
- **EMAN2** - comprehensive suite for single particle reconstruction

**Model Building & Refinement:**
- **Coot** - also widely used for cryo-EM model building
- **PHENIX** - real-space refinement tools optimized for EM maps
- **Rosetta** - de novo model building and refinement
- **ISOLDE** - interactive molecular dynamics-based modeling in ChimeraX

## **NMR Spectroscopy**

**Structure Calculation:**
- **CYANA** - automated NOE assignment and structure calculation
- **XPLOR-NIH** - structure determination using experimental restraints
- **ARIA** - automated NOE assignment with ambiguous distance restraints
- **CS-Rosetta** - structure prediction from chemical shifts

**Refinement:**
- **AMBER** - molecular dynamics refinement
- **GROMACS** - molecular dynamics simulations

## **Validation Tools**

- **MolProbity** - comprehensive validation (geometry, clashes, rotamers)
- **PROCHECK** - stereochemical quality assessment
- **WHATCHECK** - structure validation
- **PDB-REDO** - optimization and validation of PDB entries
- **EMRinger** - validation for cryo-EM structures

## **Visualization**

- **PyMOL** - molecular visualization and figure preparation
- **ChimeraX/Chimera** - visualization and analysis (especially popular for cryo-EM)
- **VMD** - molecular visualization and analysis

## **Integration Platforms**

- **CCP4i2/CCP4i** - graphical interface integrating many crystallographic tools
- **PHENIX GUI** - comprehensive interface for the PHENIX suite
- **Scipion** - integration platform for cryo-EM workflows

Most structural biology labs use combinations of these tools, often starting with automated pipelines (PHENIX, CCP4) and then using interactive tools (Coot, ChimeraX) for manual intervention. The choice often depends on the specific challenges of the structure, personal preference, and institutional availability.",,,,22.615257024765015,3,854,335,25964,,[],REDUNDANT,"PHENIX, REFMAC for refinement; SHELX, PHASER for phasing; with usage statistics","COMPLEX QUERY requiring software classification knowledge.

Databases/Resources: PDB

Knowledge Required:
- Software category traversal
- Classification filter for different stages (refinement, phasing)
- GROUP BY for usage counting
- ORDER BY for ranking

Without proper knowledge: Cannot filter by software classification.

Verified in pdb_exploration.md Pattern 5."
106,2026-02-01,Currency,What agonist drugs are available for treating metabolic disorders?,True,True,True,0.7777777777777778,"# Agonist Drugs for Metabolic Disorders

Here are the main categories of agonist drugs used in treating metabolic disorders:

## **GLP-1 Receptor Agonists** (for Type 2 Diabetes & Obesity)
- **Exenatide** (Byetta, Bydureon)
- **Liraglutide** (Victoza, Saxenda)
- **Semaglutide** (Ozempic, Wegovy, Rybelsus)
- **Dulaglutide** (Trulicity)
- **Tirzepatide** (Mounjaro, Zepbound) - dual GLP-1/GIP agonist
- **Lixisenatide** (Adlyxin)

## **PPAR Agonists** (for Diabetes & Lipid Disorders)
- **Pioglitazone** (Actos) - PPAR-gamma agonist
- **Rosiglitazone** (Avandia) - PPAR-gamma agonist
- **Fibrates** - PPAR-alpha agonists:
  - Fenofibrate
  - Gemfibrozil
  - Bezafibrate

## **Dopamine Agonists** (for Prolactin-related Metabolic Issues)
- **Bromocriptine** (Cycloset) - approved for type 2 diabetes

## **Thyroid Hormone Agonists**
- **Levothyroxine** (T4)
- **Liothyronine** (T3)
- Used for hypothyroidism affecting metabolism

## **Beta-3 Adrenergic Agonists**
- **Mirabegron** - primarily for overactive bladder, but affects metabolism
- Others in research phases for obesity

These medications work by activating specific receptors to improve glucose control, insulin sensitivity, lipid profiles, or metabolic rate depending on the specific disorder being treated.",,,9.01152515411377,50,482,True,True,0.7777777777777778,"Based on my search of biomedical databases and recent scientific literature, here are the major **agonist drugs available for treating metabolic disorders**:

## **GLP-1 Receptor Agonists** (Glucagon-Like Peptide-1)
These are highly effective for type 2 diabetes and obesity:

### For Diabetes & Obesity:
- **Semaglutide** (Ozempic, Wegovy) - [ChEMBL2108724]
- **Liraglutide** (Victoza, Saxenda) 
- **Dulaglutide** (Trulicity)
- **Exenatide** (Byetta, Bydureon)

**Key Benefits:** According to PubMed research, GLP-1 receptor agonists provide:
- Excellent glycemic control with low hypoglycemia risk
- Significant weight reduction
- Cardiovascular protection (reduced risk of heart attack, stroke, cardiovascular death)
- Kidney protection (reduced albuminuria, slower kidney function decline)
- Reduced heart failure hospitalization
- Liver benefits (regression of steatosis, prevention of fibrosis)

[DOI: 10.1016/S0140-6736(25)02105-1](https://doi.org/10.1016/S0140-6736(25)02105-1)

## **Dual GIP/GLP-1 Receptor Agonists**
- **Tirzepatide** (Mounjaro, Zepbound)

According to PubMed research, tirzepatide has shown **superior efficacy** compared to single receptor agonists for:
- Greater metabolic improvement
- More significant body composition changes
- Enhanced weight loss

[DOI: 10.1007/s13679-025-00681-5](https://doi.org/10.1007/s13679-025-00681-5)

## **PPAR Agonists** (Peroxisome Proliferator-Activated Receptor)
Used primarily for type 2 diabetes:

- **Pioglitazone** (Actos) - [ChEMBL595] - PPARγ agonist
- **Rosiglitazone** (Avandia) - PPARγ agonist

**Mechanism:** Improve insulin sensitivity, reduce insulin resistance

## **Next-Generation Agents in Development**

According to recent PubMed research, several novel multi-receptor agonists are being developed:
- **Dual GLP-1/Glucagon agonists**
- **Dual GLP-1/Amylin agonists**
- **Triple GIP/GLP-1/Glucagon agonists**
- **Small-molecule oral GLP-1 agonists** (for improved convenience)

These promise even greater efficacy, especially for weight loss, though gastrointestinal tolerability remains a challenge.

[DOI: 10.1016/S0140-6736(25)02105-1](https://doi.org/10.1016/S0140-6736(25)02105-1)

## **Safety Considerations**

According to a recent 2026 meta-analysis from PubMed:
- **Liraglutide** showed a protective effect against intestinal obstruction
- **High-dose canagliflozin** (300mg, an SGLT2 inhibitor) showed increased intestinal obstruction risk
- Most other GLP-1 agonists showed no increased obstruction risk

[DOI: 10.3390/ijms27020608](https://doi.org/10.3390/ijms27020608)

## Summary
The most clinically important agonist drugs for metabolic disorders are the **GLP-1 receptor agonists and dual GIP/GLP-1 agonists**, which have revolutionized treatment of type 2 diabetes and obesity with benefits extending to cardiovascular and kidney protection. PPAR agonists remain useful for insulin sensitization but are used less frequently due to side effect profiles.",,,,42.94638419151306,17,1569,12175,79413,"mcp__pubmed__search_articles, mcp__chembl__search_chembl_molecule, mcp__chembl__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__pubmed__get_article_metadata","[{""name"": ""mcp__pubmed__search_articles"", ""input"": {""query"": ""agonist drugs metabolic disorders treatment"", ""max_results"": 30}}, {""name"": ""mcp__chembl__search_chembl_molecule"", ""input"": {""query"": ""GLP-1 agonist"", ""limit"": ""10""}}, {""name"": ""mcp__chembl__search_chembl_molecule"", ""input"": {""query"": ""PPAR agonist"", ""limit"": ""10""}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""GLP-1 agonist"", ""limit"": 10}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""PPAR agonist"", ""limit"": 10}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""semaglutide"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""pioglitazone"", ""limit"": 5}}, {""name"": ""mcp__pubmed__get_article_metadata"", ""input"": {""pmids"": [""41596262"", ""41583490"", ""41547366"", ""41528611"", ""41525229""]}}]",VALUABLE,Agonist drugs for metabolic conditions including GLP-1 receptor agonists for diabetes,"COMPLEX QUERY requiring mechanism-indication integration.

Databases/Resources: ChEMBL

Knowledge Required:
- DrugMechanism entity for action type
- mechanismActionType = 'AGONIST' filter
- DrugIndication for metabolic disease filtering
- Cross-entity joins

Without proper knowledge: Cannot combine mechanism type with indication data.

Verified in chembl_exploration.md Pattern 5."
107,2026-02-01,Precision,What is the activity type distribution for bioactivity measurements in ChEMBL?,True,False,False,0.4444444444444444,"I don't have access to real-time ChEMBL database statistics in my training data, but I can provide you with general information about the typical activity type distribution in ChEMBL based on my knowledge.

## Common Activity Types in ChEMBL

The most prevalent activity types in ChEMBL historically include:

1. **IC50 (Half maximal inhibitory concentration)** - One of the most abundant, representing the concentration needed to inhibit a biological process by 50%

2. **Ki (Inhibition constant)** - Very common, measuring the binding affinity of an inhibitor

3. **EC50 (Half maximal effective concentration)** - Frequently used for agonist activity

4. **Potency** - General measure of compound activity

5. **Kd (Dissociation constant)** - Measures binding affinity

6. **Activity** - Generic activity measurements

7. **Inhibition (%)** - Percentage inhibition at a specific concentration

8. **MIC (Minimum inhibitory concentration)** - Common in antimicrobial assays

9. **ED50 (Median effective dose)** - Often used in in vivo studies

10. **GI50** - Growth inhibition measurements, particularly in cancer research

## General Distribution Pattern

Typically:
- **IC50** measurements often comprise 30-40% of all bioactivity data
- **Ki** values represent another 10-20%
- The remaining activity types are distributed among various other measurement types

For the most current and precise distribution statistics, you would need to query the ChEMBL database directly or check their latest release documentation.",,,9.836004734039307,55,373,True,False,0.4444444444444444,"## Activity Type Distribution in ChEMBL

Based on the ChEMBL database, there are **21,123,501 total bioactivity measurements**. Here's the distribution of the top activity types:

### Top 20 Activity Types:

1. **Potency** - 4,473,542 (21.2%)
2. **IC50** - 2,802,898 (13.3%)
3. **GI50** - 2,623,650 (12.4%)
4. **Inhibition** - 1,532,464 (7.3%)
5. **Percent Effect** - 1,328,366 (6.3%)
6. **Activity** - 1,281,656 (6.1%)
7. **Ki** - 775,444 (3.7%)
8. **MIC** - 748,009 (3.5%)
9. **EC50** - 522,752 (2.5%)
10. **INHIBITION** - 339,133 (1.6%)
11. **AC50** - 278,220 (1.3%)
12. **Kd** - 184,998 (0.9%)
13. **Z score** - 147,592 (0.7%)
14. **Ratio IC50** - 135,535 (0.6%)
15. **GI** - 129,330 (0.6%)
16. **Tissue Severity Score** - 128,999 (0.6%)
17. **Ratio** - 119,221 (0.6%)
18. **ED50** - 103,415 (0.5%)
19. **CC50** - 99,152 (0.5%)
20. **IZ** - 96,004 (0.5%)

### Key Observations:

- **Potency measurements** are the most common, representing over 21% of all activities
- **IC50 and GI50** (half-maximal inhibitory/growth inhibition concentrations) together account for about 25% of measurements
- **Binding affinity measurements** (Ki, Kd) represent a significant portion
- **Pharmacokinetic parameters** (CL, AUC, Cmax, T1/2, F) are also well-represented
- **Antimicrobial activity** (MIC, MIC50, MIC90) shows substantial coverage
- The top 10 activity types account for approximately **75%** of all bioactivity measurements

This distribution reflects ChEMBL's focus on drug discovery data, with emphasis on compound potency, inhibition constants, and efficacy measurements.",,,,35.29101490974426,21,1220,1567,106165,"mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql","[{""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""\nPREFIX cco: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT ?activityType (COUNT(?activity) AS ?count)\nWHERE {\n  ?activity a cco:Activity ;\n            cco:hasActivityType ?activityType .\n}\nGROUP BY ?activityType\nORDER BY DESC(?count)\nLIMIT 50\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""\nPREFIX cco: <http://rdf.ebi.ac.uk/terms/chembl#>\n\nSELECT ?standardType (COUNT(?activity) AS ?count)\nWHERE {\n  ?activity a cco:Activity ;\n            cco:standardType ?standardType .\n}\nGROUP BY ?standardType\nORDER BY DESC(?count)\nLIMIT 50\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""\nPREFIX cco: <http://rdf.ebi.ac.uk/terms/chembl#>\n\nSELECT (COUNT(?activity) AS ?totalActivities)\nWHERE {\n  ?activity a cco:Activity .\n}\n""}}]",CRITICAL,"Potency (4.4M), IC50 (2.8M), GI50 (2.6M), Inhibition (1.5M), Ki (775K)","SIMPLE QUERY - Straightforward activity type count.

Method: GROUP BY on activity type with COUNT

Demonstrates straightforward aggregation queries.

Verified in chembl_exploration.md simple queries section."
108,2026-02-01,Precision,What is the UniProt ID for the CRISPR-associated protein Cas9 from Streptococcus pyogenes?,True,True,True,1.0,"The UniProt ID for the CRISPR-associated protein Cas9 from Streptococcus pyogenes is **Q99ZW2**.

This is the most commonly referenced Cas9 protein, specifically from Streptococcus pyogenes serotype M1, strain SF370. This particular Cas9 variant is widely used in genome editing applications and is often referred to as SpCas9.",,,3.9270431995391846,68,97,True,True,1.0,"The **UniProt ID for Cas9 from Streptococcus pyogenes is Q99ZW2**.

This is the most well-known and widely studied Cas9 protein, specifically from *Streptococcus pyogenes* serotype M1. It's commonly referred to as:
- **SpCas9** (Streptococcus pyogenes Cas9)
- **SpyCas9** 
- CRISPR-associated endonuclease Cas9/Csn1

This is the Cas9 variant most commonly used in CRISPR-Cas9 gene editing applications. The search also shows several other Cas9 entries from different *S. pyogenes* strains, but Q99ZW2 is the canonical reference entry for this protein.",,,,18.365368127822876,9,310,1032,52279,mcp__togomcp__search_uniprot_entity,"[{""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""Cas9 Streptococcus pyogenes"", ""limit"": 10}}]",VALUABLE,Q99ZW2,"SIMPLE QUERY - Straightforward protein lookup.

Method: search_uniprot_entity('Cas9 Streptococcus pyogenes')

Demonstrates when basic protein search tools suffice.

Verified in example_questions.json question 1."
